A Bifunctional Enzyme Catalyzes the First Two Steps in N-Acetylneuraminic Acid Biosynthesis of Rat Liver

MOLECULAR CLONING AND FUNCTIONAL EXPRESSION OF UDP-N-ACETYL-GLUCOSAMINE 2-EPIMERASE/N-ACETYLGLUCOSAMINE KINASE

(Received for publication, June 3, 1997)

Roger Stäschef, Stephan Hinderlich‡, Christoph Weise§, Karin Effertz‡, Lothar Lucka‡, Petra Moormann‡, and Werner Reutter‡

From the §Institut für Molekularbiologie und Biochemie, Freie Universität Berlin, Arnimallee 22, D-14195 Berlin-Dahlem, Germany and the ¶Institut für Biochemie, Freie Universität Berlin, Thielallee 63, D-14195 Berlin-Dahlem, Germany

N-Acetylneuraminic acid (Neu5Ac) is the precursor of sialic acids, a group of important molecules in biological recognition systems. Biosynthesis of Neu5Ac is initiated and regulated by its key enzyme, N-acetylglucosamine 2-epimerase (UDP-GlcNAc 2-epimerase, EC 5.1.3.14)/N-acetylmannosamine kinase (ManNAc kinase, EC 2.7.1.60) in rat liver (Hinderlich, S., Stäschke, R., Zeitler, R., and Reutter, W. (1997) J. Biol. Chem. 272, 24313–24318). In the present paper we report the isolation and characterization of a cDNA clone encoding this bifunctional enzyme. An open reading frame of 2166 base pairs encodes 722 amino acids with a predicted molecular mass of 79 kDa. The deduced amino acid sequence contains exact matches of the sequences of five peptides derived from tryptic cleavage of the enzyme. The recombinant bifunctional enzyme was expressed in COS7 cells, where it displayed both epimerase and kinase activity.

Distribution of UDP-GlcNAc 2-epimerase/ManNAc kinase in the cytosol of several rat tissues was investigated by determining both specific enzyme activities. Secreting organs (liver, salivary glands, and intestinal mucosa) showed high specific activities of UDP-GlcNAc 2-epimerase/ManNAc kinase, whereas significant levels of these activities were absent from other organs (lung, kidney, spleen, brain, heart, skeletal muscle, and testis). Northern blot analysis revealed no UDP-GlcNAc 2-epimerase/ManNAc kinase mRNA in the non-secreting tissues.

This paper is available on line at http://www.jbc.org

EXPERIMENTAL PROCEDURES

Materials—Restriction enzymes were obtained from Life Technologies, Inc. (Gaithersburg, MD). Nitrocellulose membranes were from Schleicher & Schuell (Dassel, Germany). Nylon filters for screening, [α-32P]dATP, and [α-35S]dATP were from Amersham (Braunschweig, Germany). N-Acetyl-D-[1-14C]mannosamine and UDP-N-acetyl-D-[U-14C]glucosamine were from ICN (Eschwege, Germany). Peroxidase-conjugated swine anti-rabbit antibody was from Dako (Hamburg, Germany). Fluorescein isothiocyanate-conjugated swine anti-rabbit antibody was purchased from Dianova (Hamburg, Germany). All other chemicals were of the highest available quality and purchased from Sigma (Deisenhofen, Germany) and Merck (Darmstadt, Germany).

Preparation of Peptides and Amino Acid Sequencing—UDP-GlcNAc 2-epimerase/ManNAc kinase was purified from rat liver as described (19) and subjected to NH2-terminal sequencing by automated Edman degradation on an Applied Biosystems protein sequencer (model 473A). Peptides were generated by digestion of 20 μg of UDP-GlcNAc 2-epimerase/ManNAc kinase with 2 μg of trypsin in 100 mM Tris-HCl, pH 8.5, at 37 °C for 24 h. Peptides were separated on a reversed phase HPLC column (C18, LiChro CART CHR D, Merck) with a discontinuous gradient of 2 to 50% acetonitrile in 0.1% trifluoroacetic acid over 85 min at 0.4 ml/min, followed by 50 to 95% acetonitrile in 0.1%
Cloning of UDP-GlcNAc 2-Epimerase/ManNAc Kinase

**TABLE I**

| Peptide | Primer | Amino acid sequence | DNA sequence “rat codon usage” |
|---------|--------|---------------------|--------------------------------|
| D       | d      | LIQQWNSVLD          | CTGATCCAGAGGTGAGGAGTGGCTG      |
|         | a-d    |                     | GTTCCACTTCCCTGATCA             |
| E       | e      | VGAFGTPVNLGTR       | GTGGGCYTTCCGGACCHCGGTGATCTAAGCCTGGGCACMGV |
|         | a-e    |                     | GTGATCACTTCCCCGACCA |

**FIG. 1. Physical map and sequencing strategy for cDNA of UDP-GlcNAc 2-epimerase/ManNAc kinase (cDNA EK).** Named arrows (T3, T7, d, e, a-d, and a-e) indicate different origins of sequencing. The restriction sites were determined both from the sequence and by digestion with appropriate restriction enzymes, and are indicated along cDNA EK. The coding region (open bar above the partial restriction map of cDNA EK) and the position of the PCR-generated 546-bp DNA fragment (striped bar), which was used to screen a cDNA library of rat liver, are indicated. The beginning of the coding region is indicated by ATG and the end is indicated by ter. The positions of peptides (A, B, C, D, and E) derived by tryptic digestion and reversed phase HPLC separation are also shown in relation to the cDNA sequence of UDP-GlcNAc 2-epimerase/ManNAc kinase.

trifluoroacetic acid over 25 min at 0.4 ml/min. Effluent samples showing peaks of absorbance at 215 nm were collected and concentrated to 20 μl before peptide sequencing.

cDNA Library and Nucleotide Sequencing—Total RNA was extracted from rat liver tissue in an acidic guanidinium thiocyanate/phenol/chloroform mixture (20). Reverse transcription of poly(A) RNA with oligo(dT)15 primers was done using Moloney murine leukemia virus reverse transcriptase (Life Technologies, Inc.). The resulting reverse transcripts were used directly for PCR. Primers for PCR were designed from peptide sequences, taking into consideration the rat codon usage frequencies.

Cloning of UDP-GlcNAc 2-Epimerase/ManNAc kinase (cDNA EK) was subcloned into the eucaryotic expression vector pBK-CMV (Stratagene). COS7 cells were then transiently transfected with this construct using the calcium phosphate method (23). After 20 h, the calcium phosphate precipitate was removed and cells were further cultured in Dulbecco’s modified Eagle’s medium containing 10% fetal calf serum for 24 h and then selected with 600 μg/ml G418. Expression of UDP-GlcNAc 2-epimerase/ManNAc kinase was monitored by immunofluorescence, immunoblotting, and determination of enzyme activity in cell lysates.

Immunofluorescence—For immunofluorescence, cells were grown on coverslips, fixed in solution containing 3% formaldehyde and permeabilized with 0.1% Triton X-100. Cells were blocked with 3% bovine serum albumin and then incubated with polyclonal antibody at room temperature. The polyclonal antiserum directed against UDP-GlcNAc 2-epimerase/ManNAc kinase was obtained by the method of Bouard and Leroisey (24). Cells were then incubated with fluorescein isothiocyanate-conjugated anti-rabbit antibody and imaged by fluorescence microscopy.

Immunoblot Analysis—Cell lysates of COS7 were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis as described by Laemmli (25) using 10% acrylamide gels. Separated proteins were electrophoresed onto nitrocellulose membranes. The membranes were blocked for 12 h in 5% skim milk in buffer A (0.1% Tween 20, 150 mM NaCl, 3 mM KCl in 9 mM NaH2PO4, pH 7.2) and then incubated for 1 h in a 1/2000 dilution of polyclonal anti-UDP-GlcNAc 2-epimerase/ManNAc kinase antiserum in buffer A. Detection was performed using a peroxidase-conjugated swine anti-rabbit secondary antibody and an enhanced chemiluminescence (ECL) detection kit from Amersham.

Preparation of Tissue Cytosols—Male Wistar rats were perfused with 20 ml of 150 mM NaCl while the animals were under light ether anesthesia. Organs were removed and transferred to 2 volumes of homogenizing buffer containing 10 mM Na2PO4, pH 7.5, 1 mM EDTA, 1 mM dithiothreitol, 0.5 mM mannose, 0.1 mM UDP, and 1 mM phenylmethylsulfonyl fluoride. The tissues were homogenized with an Ultra-turrax for 1 min at 10,000 rpm. The homogenates were ultracentrifuged at 100,000 × g for 60 min.

Expression of UDP-GlcNAc 2-Epimerase/ManNAc Kinase—UDP-GlcNAc 2-epimerase/ManNAc kinase coding cDNA from pBluescript II was assayed as described (19). Tissue distribution was determined by...
assaying ManNAc kinase in the presence of 5 mM N-acetylglucosamine (GlcNAc) to inhibit the ManNAc kinase activity of N-acetylglucosamine kinase (GlcNAc kinase) (26). Protein concentration was determined according to the method of Bradford (27), using bovine serum albumin as standard.

**RESULTS**

**Protein Sequencing and Amplification of cDNA Fragments by PCR**—Amino acid sequences of five selected peptides were obtained after tryptic digestion of purified UDP-GlcNAc 2-epimerase/ManNAc kinase. The sequences of peptide D and peptide E were used for designing oligonucleotide primers (d, e, a-d, and a-e, where a-d and a-e are the antisense sequences of primers d and e, respectively) for PCR, taking into consideration the predicted amino acid sequence for the NH2 terminus.

The sequence data will appear in the EMBL/GenBank/DDBJ Nucleotide Sequence Data Libraries under accession number Y07744.
ation the rat codon usage (Table I). First, a DNA fragment of 546 bp was amplified from rat liver cDNA with primer e and primer a–d. The 546-bp DNA fragment was cloned in pCR II and then sequenced. The deduced amino acid sequence of the amplified fragment contained a complete match of peptide A.

**Nucleotide Sequence and Deduced Amino Acid Sequence**—The 546-bp DNA fragment was used to screen a cDNA library of rat liver. Eight hybridization positive clones were identified. After plaque purification and rescreening, DNA was prepared from each clone and characterized by restriction analysis. The partial restriction map of the longest cDNA clone, which was designated cDNA EK, is shown in Fig. 1. The additional seven clones had overlapping restriction maps. cDNA EK was chosen for further characterization. PCR primers d, e, a–d, and a–e were used as sequencing primers. Additional primers were constructed from the newly obtained sequence, and the complete cDNA sequence of UDP-GlcNAc 2-epimerase/ManNAc kinase was determined in both directions. The strategy used for

![Fig. 3. Mapping of phosphate-binding subdomains in UDP-GlcNAc 2-epimerase/ManNAc kinase](image)

**Fig. 3._mapping of phosphate-binding subdomains in UDP-GlcNAc 2-epimerase/ManNAc kinase.** The diagram aligns putative phosphate-binding subdomains of the ATPase domain in UDP-GlcNAc 2-epimerase/ManNAc kinase and several hexokinases. Abbreviations are: 2EPI_RAT, UDP-GlcNAc 2-epimerase/ManNAc kinase; HXK1_RAT, rat hexokinase 1; HXK2_RAT, rat hexokinase 2; HXK3_RAT, rat hexokinase 3; HXKH_RAT, rat glucokinase; HXKB_Yeast, yeast hexokinase B; PBD, phosphate-binding subdomain. Letters at PBD represent the amino acid nomenclature of Bork et al. (32) derived from sequence similarities of the ATP-binding domains of sugar kinases, actin, and hsp 70: h, purely hydrophobic (VLIFWY); f, partially hydrophobic (VLIFWYMCGATKHR); t, tiny (GSAT); s, small (GSATNDVCP); p, tiny plus polar (GSAT-NDQEKHR). Underlined amino acids match with PBD amino acids. Shadowed amino acids match of UDP-GlcNAc 2-epimerase/ManNAc kinase with other hexokinases.

![Fig. 4. Transient expression of UDP-GlcNAc 2-epimerase/ManNAc kinase in COS7 cells](image)

**Fig. 4. Transient expression of UDP-GlcNAc 2-epimerase/ManNAc kinase in COS7 cells.** COS7 cells were transfected with either expression plasmid pBK-CMV (pBK) or cDNA EK in expression plasmid pBK-CMV (pBK:cDNA EK). Non-transfected COS7 cells (COS7 (control)) served as the negative control. a, immunofluorescence; b, immunoblotting of cell lysates: lane 1, non-transfected COS7 cells; lane 2, COS7 cells transfected with pBK; lane 3, rat liver cytosol; lane 4, COS7 cells transfected with pBK:cDNA EK; molecular mass markers are indicated on the left. c, determination of catalytic activity of UDP-GlcNAc 2-epimerase and ManNAc kinase in cell lysates.
deducing the nucleotide sequence is illustrated in Fig. 1. The determined DNA sequence of 2508 bp included the 546-bp long PCR-generated DNA fragment from bp 990 to bp 1536. The sequence of the leading strand is shown in Fig. 2. Examination of the nucleotide sequence showed an open reading frame starting at position 48 and ending at position 2213. The reading frame of 2166 nucleotides encoded 722 amino acids (Fig. 2). The deduced amino acid sequence contained complete matches for all five peptides of the digested UDP-GlcNAc 2-epimerase/ManNAc kinase. The position of these peptides with respect to the DNA sequence is shown in Fig. 1 and the sequences of these peptides within the 75-kDa polypeptide are shadowed in Fig. 2.

The initiation codon ATG is part of a complete consensus motive for eucaryotic translation (28). The 3′-terminal noncoding region includes the polyadenylation signal (29) from nucleotide 2497 to nucleotide 2502 (Fig. 2). Two potential asparagine-linked glycosylation sites with -Asn-Xaa-Ser- as consensus sequence were identified at amino acid positions 300 and 395, but no glycosyl residues were detected in the purified UDP-GlcNAc 2-epimerase/ManNAc kinase when assayed by peptide N-glycosidase F digestion and separation of the products by ion exchange chromatography by the method of Nuck et al. (30) (data not shown). In addition, no potential transmembrane spanning sequences or signal sequences for glycosylphosphatidylinositol anchoring were detectable, suggesting that UDP-GlcNAc 2-epimerase/ManNAc kinase is translated on free ribosomes as a cytosolic protein, and therefore has no opportunity to undergo N-glycosylation.

**Determination of Sequence Similarity**—Searches of EMBL/GenBank and SWISS-PROT sequence data showed that no identical sequence has been reported so far. In addition, we compared the amino acid sequence of UDP-GlcNAc 2-epimerase/ManNAc kinase with the known sequences of 13 UDP-GlcNAc-binding enzymes, 15 UDP-glucose 4-epimerases, and 12 other epimerases, including the sequence of porcine GlcNAc 2-epimerase (31). The comparison revealed no similarities which may indicate the localization of the UDP-GlcNAc 2-epimerase domain within the bifunctional enzyme. Comparison with the sequences of several hexokinases (Fig. 3) revealed good matches at positions which are typical for phosphate-binding subdomains in ATPase domains of sugar kinases (Fig. 3) (32).

**Expression of UDP-GlcNAc 2-Epimerase/ManNAc Kinase**—To confirm that UDP-GlcNAc 2-epimerase/ManNAc kinase is the product of, and can be directly functionally expressed by, the cloned cDNA, cDNA EK was expressed in COS7 cells which were low in detectable UDP-GlcNAc 2-epimerase/ManNAc kinase activity. The recombinant plasmid pbKcDNA EK contained the 2.5-kilobase pair cDNA EK fragment between XbaI and XhoI sites of the vector pbKc-CMV. COS7 cells were then transfected with pbKcDNA EK. Transfected cells were found to show an increased intensity of immunofluorescence in the cytosol (Fig. 4a). Immunoblot analysis of the cell lysates of transfected cells with a polyclonal antibody directed against rat liver UDP-GlcNAc 2-epimerase/ManNAc kinase revealed a polypeptide showing the same mobility as native UDP-GlcNAc 2-epimerase/ManNAc kinase on SDS-polyacrylamide gel electrophoresis (Fig. 4b). In cell lysates expressing the 75-kDa polypeptide the activities of UDP-GlcNAc 2-epimerase and ManNAc kinase were five times greater than those in cell lysates of either pbKCMV-containing strains or nontransfected strains of COS7 cells (Fig. 4c).

**Tissue Distribution of UDP-GlcNAc 2-Epimerase/ManNAc Kinase**—The enzyme activities of UDP-GlcNAc 2-epimerase/ManNAc kinase were determined in the cytosols of 10 different rat tissues. Enzyme activities were only found in liver, salivary glands, and intestinal mucosa, whereas activities of UDP-GlcNAc 2-epimerase/ManNAc kinase in the cytosols of brain, heart, kidney, lung, skeletal muscle, spleen, and testis were below the detectable level (Table II). mRNA analysis was used to determine whether the tissues showing no UDP-GlcNAc 2-epimerase/ManNAc kinase activity contained even small amounts of the enzyme. Rat mRNA of liver, brain, heart, kidney, lung, skeletal muscle, spleen, and testis were probed at high stringency with the radiolabeled 546-bp DNA fragment. Liver showed a dominant signal at 2500 nucleotides corresponding to the cDNA of UDP-GlcNAc 2-epimerase/ManNAc kinase, but no positive hybridization signal was obtained with the mRNA of the other investigated tissues (Fig. 5).

**DISCUSSION**

Recently we found that the two enzymes initiating the biosynthesis of Neu5Ac (UDP-GlcNAc 2-epimerase and ManNAc kinase) are parts of one bifunctional enzyme (19). Here we present the complete sequence of the cDNA encoding the bifunctional enzyme. The 722 amino acids derived from the open reading frame of the cDNA have a predicted molecular mass in agreement with that of the native enzyme, and contain exact matches of five peptides obtained from tryptic digestion of UDP-GlcNAc 2-epimerase/ManNAc kinase. Expression of the cDNA in COS7 cells resulted in a 75-kDa polypeptide, as well as increased activities of UDP-GlcNAc 2-epimerase and ManNAc kinase. We therefore conclude that the cDNA of the 75-kDa polypeptide encodes the bifunctional enzyme UDP-GlcNAc 2-epimerase/ManNAc kinase.

A bifunctional enzyme normally consists of two distinct domains containing separate catalytic sites. As demonstrated for mouse ATP sulfurylase/adenosine 5′-phosphosulfate kinase (33) it is possible to determine these domains from their similarity to known sequences encoding separated enzymes with

| Tissues            | UDP-GlcNAc 2-epimerase | ManNAc kinase |
|--------------------|------------------------|--------------|
| Liver              | 3.1 ± 1.1              | 6.5 ± 1.7    |
| Salivary glands    | 0.5 ± 0.2              | 1.7 ± 0.4    |
| Intestinal mucosa  | 0.3 ± 0.1              | 1.0 ± 0.2    |
| Lung               | <0.1                   | <0.1         |
| Spleen             | <0.1                   | <0.1         |
| Kidney             | <0.1                   | <0.1         |
| Testis             | <0.1                   | <0.1         |
| Brain              | <0.1                   | <0.1         |
| Heart              | <0.1                   | <0.1         |
| Skeletal muscle    | <0.1                   | <0.1         |
equal or similar properties. Although we compared the amino acid sequence of UDP-GlcNAc 2-epimerase/ManNAc kinase with several sequences of enzymes using UDP-GlcNAc as a substrate or catalyzing an epimerase reaction, we were not able to determine the localization of the UDP-GlcNAc 2-epimerase domain. Comparison with the ATP-binding domains of hexoki-

nases revealed good matches for two phosphate-binding sites in the COOH-terminal half of the sequence (Fig. 3). The same area also contains a leucine zipper-like motif which participates in dimerization of DNA-binding proteins and membrane proteins (33, 34). This motif may be responsible for the higher stability of the dimeric structure that displays ManNAc kinase activity, although no cytosolic protein has yet been reported in which the leucine zipper motif plays a functional role. We therefore assume that the COOH-terminal part of the UDP-GlcNAc 2-epimerase/ManNAc kinase sequence contains the kinase domain.

Sialic acids are widely distributed in mammalian tissues and one might assume that sialic acid synthesizing enzymes occur in all tissues containing sialic acids. This assumption is not supported by Northern blot analysis, which failed to detect mRNA for UDP-GlcNAc 2-epimerase/ManNAc kinase in the examined tissues, in particular in brain, lung, and kidney, which definitely express sialic acids (36). Tissues with a low requirement for sialic acids may replenish their sialic acid pool with Neu5Ac from oligosaccharide turnover (2, 37). Maru et al. (31) reported an alternative pathway for the biosynthesis of Neu5Ac, in which ManNAc is directly synthesized from GlcNAc by the action of N-acetylglucosamine 2-epimerase, which occurs in most rat tissues (38). But the activity of ManNAc kinase is directly linked to that of UDP-GlcNAc 2-epimerase by the bifunctionality of UDP-GlcNAc 2-epimerase/ManNAc kinase. In this case GlcNAc kinase, occurring in several rat tissues (39), may phosphorylate ManNAc (26). A very appropriate method for testing for an alternative pathway of Neu5Ac biosynthesis is to construct a gene knock-out of UDP-GlcNAc 2-epimerase/ManNAc kinase in mouse. The prerequisite for this experiment is given with the results presented here.

Acknowledgments—We thank Eva Guhl for technical assistance and Dr. T. A. Scott for improving the English of this manuscript.

REFERENCES

1. Varki, A. (1992) *Glycobiology* 2, 24–40
2. Schauer, R., Kelm, S., Reuter, G., Boggesen, P., and Shaw, L. (1995) in *Biology of the Sialic Acids* (Rosenberg, A., ed) pp. 7–67, Plenum Press, New York
3. Varki, A. (1993) *Glycobiology* 3, 97–130
4. Reutter, W., Stäsche, R., Stehling, P., and Baum, O. (1997) in *Glycosciences: Status and Perspectives* (Gabius, H.-J., and Gabius, S., eds) pp. 245–259, Chapman and Hall, Weinheim
5. Edelman, G. M., and Crossin, K. L. (1991) *Annu. Rev. Biochem.* 60, 155–190
6. Yang, P., Major, D., and Rutishauser, U. (1994) *J. Biol. Chem.* 269, 23039–23044
7. Karlsson, K.-A. (1995) *Curr. Opin. Struct. Biol.* 5, 622–635
8. Rens-Domiano, S., and Reisene, T. (1991) *J. Biol. Chem.* 266, 20994–21002
9. Pirie-Shepherd, S. R., Jett, E. A., Andon, N. L., and Pizzo, S. V. (1995) *J. Biol. Chem.* 270, 5877–5881
10. Hakomori, S. (1989) *Adv. Cancer Res.* 52, 257–331
11. Bhavanandan, V. P. (1991) *Glycobiology* 1, 493–503
12. Roth, J., Zuber, C., Wagner, P., Taatsjes, D. J., Weisgerber, C., Heitz, P. U., Goridis, C., and Bitter-Suermann, D. (1988) *Proc. Natl. Acad. Sci. U. S. A.* 85, 2999–3003
13. Dennis, J. W., Laferte, S., Fukuda, M., Delli, A., and Carver, J. P. (1986) *Eur. J. Biochem.* 161, 359–373
14. Sawada, R., Tsuibi, S., and Fukuda, M. (1994) *J. Biol. Chem.* 269, 1425–1431
15. Basu, S., Basu M., and Basu S. S. (1995) in *Glycobiology: Biology of the Sialic Acids* (Rosenberg, A., ed) pp. 7–67, Plenum Press, New York
16. Kayser, H., Zeitler, R., Kannicht, C., Grunow, D., Nuck, H., and Reutter, W. (1992) *J. Biol. Chem.* 267, 16934–16938
17. Keppler, O. T., Stehling, P., Herrmann, M., Kayser, H., Grunow, D., Reutter, W., and Pavilta, M. (1995) *J. Biol. Chem.* 270, 1308–1314
18. Warren, L. (1972) in *Glycoproteins* (Gottschalk, A., ed) pp. 1097–1126, Elsevier Publishing Co., Amsterdam, London
19. Hinderlich, S., Stäsche, R., Zeitler, R., and Reutter, W. (1997) *J. Biol. Chem.* 272, 24313–24318
20. Chomczynski, P., and Sacchi, N. (1987) *Anal. Biochem.* 162, 156–159
21. Sanger, F., Richmond, S., and Coulson, A. R. (1977) *Proc. Natl. Acad. Sci. U. S. A.* 74, 5463–5467
22. Feinberg, A. P., and Vogelstein, B. (1983) *Biochem. Biophys. Res. Commun.* 111, 47–54
23. Graham, F. L., and van der Eb, A. J. (1973) *Virology* 52, 456–462
24. Boulard, C., and Leray, A. (1983) *J. Immunol. Methods* 50, 221–226
25. Lennm, R. (1970) *Nature* 227, 680–685
26. Allen, M. B., and Walker, D. G. (1980) *Biochem. J.* 185, 577–582
27. Bradford, M. M. (1976) *Anal. Biochem.* 72, 248–254
28. Kozak, M. (1991) *J. Biol. Chem.* 266, 19867–19870
29. Wickens, M., and Stephenson, P. (1984) *Science* 226, 1045–1051
30. Nuck, R., Zimmermann, M., Sauvageot, D., Josic, D., and Reutter, W. (1990) *Glycoconjugate J.* 7, 279–286
31. Maru, I., Ohta, Y., Murata, K., and Tsukada, Y. (1996) *J. Biol. Chem.* 271, 16284–16299
32. Bork, P., Sander, C., and Valencia, A. (1992) *Proc. Natl. Acad. Sci. U. S. A.* 89, 7290–7294
33. Li, H., Deyrup, A., Mensch, J. R., Jr., Domowicz, M., Konstantinidis, A. K., and Schwartz, N. B. (1995) *J. Biol. Chem.* 270, 29453–29459
34. Struhl, K. (1989) *Trends Biochem. Sci.* 14, 137–140
35. Pessino, A., Hebert, D. N., Woon, C. W., Harrison, S. A., Clancy, B. M., Buxton, J. M., Carruthers, A., and Czech, M. P. (1991) *J. Biol. Chem.* 266, 20213–20217
36. Reutter, G., and Gabius, H. J. (1996) *Biochim. Hoppe-Seyler* 377, 325–342
37. Saito, M., and Yu, R. K. (1995) in *Glycobiology: Biology of the Sialic Acids* (Rosenberg, A., ed) pp. 7–67, Plenum Press, New York
38. Datta, A. (1970) *Biochemistry* 9, 3363–3370
39. van Rijnau, J., van Dijk, W., Hooghwinkel, G. J. M., and Ferwerda, W. (1983) *Biochem. J.* 210, 21–28